Curebase and Adaptive Biotechnologies Collab to Expand Study Access

Curebase and Adaptive Biotechnologies Corp. have announced an ongoing research collaboration to broaden patient participation in Adaptive’s clinical studies. The initial two studies of the partnership involve Adaptive’s T-Detect diagnostic test. T-Detect is under development for multiple diseases translating the natural diagnostics capability of T-Cells into clinical practice.

The first study will validate the effectiveness of T-Detect for patients with Lyme disease. Lyme disease tends to impact people in rural areas, where a lack of clinical research sites makes it more challenging to recruit participants for clinical studies. In a second study, the two companies will collect and analyze long-term data from COVID-19 patients who have used Adaptive’s T-Detect COVID clinically available test.